T80.51XD Anaphylactic reaction due to administration of blood and blood products, subsequent encounter

Name of the Condition

• Anaphylactic reaction due to administration of blood and blood products, subsequent encounter.

Summary

This condition describes a severe, systemic allergic reaction occurring after exposure to blood or blood products, documented as a subsequent encounter. It is a rapid-onset, life-threatening response involving multiple organ systems, requiring immediate medical intervention. The reaction is specific to blood and blood product administration and is classified as a subsequent encounter, indicating follow-up care.

Causes

Anaphylactic reactions to blood and blood products occur when the immune system overreacts to proteins or other components in these substances, releasing histamine and other mediators. This can result from administration of blood transfusions, plasma products, or other blood-derived therapies. The reaction is triggered by immune recognition of foreign proteins or antigens in the administered products.

Risk Factors

• Prior exposure to blood or blood products
• Known allergies to blood components (e.g., plasma proteins)
• History of severe allergic reactions (anaphylaxis)
• Underlying atopic conditions (e.g., asthma, eczema)
• Administration of high-risk blood products (e.g., plasma, platelets)

Symptoms

• Sudden onset of hives, itching, or flushing
• Swelling of the lips, tongue, or throat
• Difficulty breathing or wheezing
• Rapid heartbeat or hypotension
• Nausea, vomiting, or abdominal cramps
• Dizziness, fainting, or loss of consciousness

Diagnosis

Diagnosis is based on clinical presentation, including rapid symptom onset after blood or blood product exposure, and exclusion of other causes. Skin testing or specific IgE testing may confirm the allergy, but treatment often precedes confirmatory testing. Documentation of the reaction’s timing relative to the administration and the specific blood product involved is critical.

Treatment Options

Immediate treatment includes epinephrine administration, airway management, and supportive care. Antihistamines, corticosteroids, and bronchodilators may be used adjunctively. Discontinuation of the offending blood product is essential. Long-term management may involve avoidance of the trigger and patient education on emergency response.

Prognosis and Follow-Up

With prompt treatment, most patients recover fully. Follow-up care focuses on identifying the specific trigger, educating the patient on avoidance, and prescribing emergency medications (e.g., epinephrine auto-injectors). Subsequent encounters may involve monitoring for delayed reactions or assessing tolerance to alternative products.

Complications

• Respiratory failure requiring mechanical ventilation
• Cardiovascular collapse or shock
• Laryngeal edema leading to airway obstruction
• Multi-organ dysfunction in severe cases

Lifestyle & Prevention

• Avoidance of the specific blood or blood product identified as the trigger
• Use of pre-medication protocols (e.g., antihistamines, corticosteroids) for future transfusions, if necessary
• Carrying emergency medications (e.g., epinephrine) as prescribed
• Wearing medical alert identification for known allergies

When to Seek Professional Help

Seek immediate medical attention if symptoms of anaphylaxis occur after blood or blood product administration, including difficulty breathing, swelling, or dizziness. Delayed reactions or worsening symptoms also warrant prompt evaluation.

Tips for Medical Coders

Document the specific blood or blood product involved, the timing of the reaction relative to administration, and the encounter type (subsequent). Ensure clinical notes support the anaphylactic nature of the reaction and the follow-up context. Code T80.51XD is appropriate for subsequent encounters; initial encounters or acute episodes use different codes.